Aster DM Healthcare ka Q3 Blast! QCIL Merger ne kiya kamaal, Revenue **15%** up, Ab **25%** Profit margin ka target!

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorIshaan Verma|Published at:
Aster DM Healthcare ka Q3 Blast! QCIL Merger ne kiya kamaal, Revenue **15%** up, Ab **25%** Profit margin ka target!
Overview

Are you guys ready for some big news? Aster DM Healthcare ne Q3 FY26 mein waahiyat performance dikhaya hai! QCIL ke saath merge hone ke effect se proforma revenue **15%** YoY badhkar **₹2,366 crore** ho gaya. Operating EBITDA mein toh **22%** ka jump aaya, jo **₹503 crore** tak pahunch gaya, matlab **21%** margin! Standalone operations bhi **13%** grow hue. Management expects synergies se future mein **24-25%** EBITDA margins milenge.

Toh, sabse pehle combined figures ko thoda aur detail mein dekhte hain. Ye jo Quality Care India Ltd (QCIL) wala merger chal raha hai na, uske baad company ka combined proforma revenue 15% tak ₹2,366 crore pahunch gaya. Operating EBITDA mein 22% ki tezi aayi, jo ₹503 crore ho gaya aur margin 21% raha. Yeh numbers dikha rahe hain ki integration se pehle hi positive signs mil rahe hain.

Ab sirf Aster DM Healthcare ki standalone baat karein toh, unka revenue 13% badhkar ₹1,186 crore raha. Isme Kasargod hospital ka launch aur Oncology jaise high-value services ka bada role raha. Aur QCIL bhi akeli 17.3% revenue growth aur 32.0% EBITDA jump ke saath ₹279 crore tak pahunchi, jismein unka margin 23.7% tha. Dono milkar ek powerhouse banne ki taraf badh rahe hain!

Company ki financial health bhi zabardast hai. Unke paas ₹1,255 crore cash hai aur sirf ₹631 crore ka gross debt hai. ROCE 22.1% par hai, matlab paisa accha return de raha hai. Aur capacity badhane ke liye is 9 mahine mein ₹406 crore ka Capex bhi kiya gaya hai.

Merger abhi bhi track par hai, shareholder meetings February-March 2026 mein hongi aur Q1 FY27 tak pura hone ki ummeed hai. Management ne bola hai ki is merger se aage 2-3 saal mein EBITDA mein 10-15% tak ka improvement aa sakta hai. Goal hai combined entity ke liye 24-25% EBITDA margin achieve karna. Aur sirf margin hi nahi, bed capacity bhi 10,620 se badhkar 14,710+ beds tak pahunchane ka plan hai. Aster standalone ki capacity bhi 5,451 se 7,800+ beds tak expand hogi.

Operational side pe bhi company ne advanced tech jaise LINACs aur robotic surgery mein invest kiya hai. Complex care par focus badha hai. Ek ₹27.9 crore ka exceptional item bhi tha, jo labour code changes ki wajah se hua tha, isse net profit par thoda asar pada, par ye ek baar ka kharcha hai.

Abhi kuch challenges bhi hain, jaise QCIL ko integrate karna aur synergies ko time pe realize karna. Badhti capacity ko manage karna bhi ek factor hai. Par overall, outlook bahut positive hai. Investors ab merger completion aur expansion plans ko follow karenge. Agar sab kuch plan ke hisaab se chala toh Aster DM Healthcare aage chal kar healthcare sector mein ek major player banega.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.